BioSpace News Archive

Ribon Therapeutics to Present at the Piper Sandler 32 nd Annual Virtual Healthcare Conference

Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced participation in the following conferences during the month of November: 2020 Virtual Guggenheim Healthcare Talks | Idea Forum | Neuro/Immunology Day One-on-one meetings Monday, November 16, 2020 Virtual Fall Investor Summit P

- Apple Tree Partners (ATP), a leading life sciences venture firm, today announced the launch of Nereid Therapeutics, a company dedicated to discovering new disease treatments by applying pioneering research and technologies in biomolecular condensates. ATP created Nereid with Clifford P. Brangwynne , Ph.D., professor in the Department of

XOMA Corporation announced it has earned a $2 million milestone payment from Takeda Pharmaceutical Company Limited as the first patient has been dosed in its Phase 2 study to evaluate safety, tolerability, and efficacy of mezagitamab in participants with generalized myasthenia gravis.

Biogen earns top scores on areas including access to medicine, talent attraction, innovation management and climate performance and reporting

Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced that management is scheduled to participate in two upcoming virtual investor conferences.

Cytokinetics, Incorporated announced that new findings from analyses of claims data and electronic health records related to heart failure and hypertrophic cardiomyopathy were shared in three poster presentations at the American Heart Association Scientific Sessions 2020.

Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment of rare diseases, announced that the European Medicines Agency has granted orphan designation for ARU-1801, an investigational lentiviral gene therapy.

Day-90 Analysis of FX-322 Phase 2a Study for Acquired Sensorineural Hearing Loss (SNHL) Planned for Late Q1 2021; End of Study Readout Planned in Late Q2 2021

Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the Jefferies Virtual London Healthcare Conference. Gerald Herman, Chief Financial Officer, will participate in an analyst moderated question and answer session on behalf of the company on Wednesday, November 18, 2020 at 2:05 PM Greenwich Mean Time (9:05 AM Eastern Standard Time). A live audio webcast of the question and answer session will